Advanced Bitcoin Technologies AG Q1 FY2025 Earnings Call

· Earnings call transcript and AI-powered summary

  • Overall Performance: Abbott delivered a strong Q1, with sales up 7% year-over-year (YoY), increasing to 8.3% when excluding COVID-19 testing sales. Adjusted EPS was $1.09, a growth of 11% YoY, finishing at the high end of the company’s guidance range.
  • Margins: Gross margin expanded by 140 basis points (bps), and operating margin improved by 130 bps compared to Q1 2024. Adjusted gross margin was 57.1% of sales, with adjusted SG&A at 29.5% of sales. Adjusted R&D spending was 6.7% of sales.
  • Foreign Exchange Impact: FX negatively impacted Q1 sales by 2.8% YoY. However, a recent weakening of the US dollar provided some offset.
  • Tariffs: Abbott expects tariffs to have a financial impact starting Q3 2025, estimating a “few hundred million dollars” for the second half of the year. Tariffs are expected to equally impact U.S. and China operations. Despite this, the company reaffirmed its full-year EPS guidance due to mitigation strategies including FX, interest, tax management, and its global manufacturing network of 90 facilities.
  • Q2 Guidance: Adjusted EPS forecasted in the range of $1.23 to $1.27. Full-year organic sales growth is expected between 7.5% and 8.5%.

Segment Performance

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning, and thank you for standing by. Welcome to Abbott Laboratories' First Quarter 2025 Earnings Conference Call. Participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star one one keys on your touch-tone phone. This call is being recorded by Abbott Laboratories. With the exception of any participants' questions asked during the question and answer session, the entire call, including the question and answer session, is material copyrighted by Abbott Laboratories. It cannot be recorded or rebroadcast without Abbott Laboratories' expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Mike Comilla: Good morning, everyone, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance, and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2025. Abbott Laboratories cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the for

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional